Yellow fever is an acute viral fever caused by a mosquito-borne flavivirus. Most of these infections are asymptomatic. In those individuals who develop the condition, the clinical spectrum ranges from nonspecific flu-like illness with fever, malaise, prostration, headache, photophobia, generalized arthralgia and myalgia, nausea, and/or vomiting to potentially lethal pan systemic disease, most prominently involving the liver, kidneys, GI tract, and brain, with recrudescing fever, jaundice, renal failure, severe hemorrhage due to thrombocytopenia, and shock. The case mortality rate of yellow fever varies extensively in different studies but is typically 20% or higher. Jaundice or other gross evidence of severe liver disease is associated with higher mortality rates. In terms of revenue, the Global Yellow Fever Vaccine Market was valued at US$ 56.63 Mn in 2016 and is expected to reach US$ 81.75 Mn by 2025, expanding at a CAGR of 4.3% from 2017 to 2025.